Collegium Pharmaceutical, Inc. (NasdaqGS: COLL)
Health Care · Pharmaceuticals · US
$27.35
+0.89% today · -29.5% 1Y
Collegium Pharmaceutical, Inc. (NasdaqGS: COLL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $890.40M and employs 423 people.
Over the last twelve months the share price has lost 29.5%, trading between 25.47 and 50.79.
Tweenvest scores Collegium Pharmaceutical, Inc. across four factors: quality 64/100, value 68/100, growth 91/100. Its strongest factor is growth.
COLL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $890.40M
- Revenue (TTM)
- $808.21M
- P/E
- 19.46
- EPS
- 1.41
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- $50.79
- 52-week low
- $25.47
- Avg volume (3M)
- —
- Shares outstanding
- 32.56M
- Employees
- 423
- Next earnings
- —
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
- ISIN
- US19459J1043
- Founded
- 2002
- Listed since
- May 7, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.58 | +0.05% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.39 | -0.60% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.23 | +0.38% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.